Identify treatable tumour DNA biomarkers with a single blood test.

Guardant 360

THE Global Leader in LIQUID BIOPSY

  • Simple blood test
  • Full or critical exon coverage of 74 genes + MSI status from Circulating Tumour DNA (ctDNA)
  • Includes full range of genetic mutations:

- single nucleotide variations (SNVs)

- insertions/deletions (INDELs)

- copy number alterations (CNAs)

- fusions

- microsatellite instability status (MSI)

  • Proprietary published targeted digital DNA sequencing method
  • Real time information (ctDNA 90 minute half life)
  • Published quality metrics:

- robust assay with low failure rate (<1%)

- high sensitivity across range of mutant allele 
   fractions (MAF)

- very high specificity

- strong correlation with tissue biomarkers

  • Clinical response map with serial blood tests over time
  • Identifies FDA approved therapies and available clinical trials


Enquire about a Test

Testing is by referral from an Oncologist, medical or surgical specialist. For more information contact us:


e:   info@sequenca.nz

m: 021 021 57344

p:  09 524 7664

Got a question?

Submitting Form...

The server encountered an error.

Form received.